格隆汇12月31日丨济民健康(603222.SH)公布，截至2025年12月31日，公司通过集中竞价交易方式累计 回购股份306.05万股，占公司总股本的比例为0.58%，购买的最高价为9.75元/股，最低价为5.87元/股， 已支付的总金额为2198.38万元（不含交易费用）。 ...

证券日报网讯 12月29日，济民健康在互动平台回答投资者提问时表示，公司成立新的合资公司核心目 的为公司培育和整合优质标的资产，推动公司产业转型升级，增强公司核心竞争力及可持续发展能力。 （编辑 丛可心） ...

Group 1 - Hubei Jimin Military-Civilian Technology Innovation Co., Ltd. has been established with a registered capital of 600 million yuan [1] - The company's business scope includes integrated circuit design, software development, information system integration services, and information technology consulting services [1] - Jimin Health holds 100% ownership of the newly established company [1]

Group 1 - Shareholder of Okoyi plans to reduce holdings by up to 1.89% of the company's shares, amounting to a maximum of 3 million shares due to personal funding needs [1] - Tianchuang Fashion is planning a change in control, leading to continued suspension of its stock trading, expected to last no more than 3 trading days [2] - China Electric Power Construction Company reported a new contract amount of 10,317.55 billion yuan for the first 11 months of 2025, a year-on-year decrease of 1.65% [3] Group 2 - Pilin Bio's wholly-owned subsidiary received approval for a clinical trial of a drug, indicating progress in its product development [4] - Yihong Medical obtained two medical device registration certificates for diagnostic kits, enhancing its product portfolio [5] - Aohong Electronics plans to use up to 450 million yuan of idle fundraising for cash management, targeting safe and liquid financial products [6] Group 3 - China Electric Power Construction signed a contract worth approximately 6.626 billion yuan for a natural gas booster station project in Turkey, with a construction period of about 55 months [7] - Baosheng Co. won a bid for a power cable project in Singapore, valued at around 1.2 billion yuan, marking the largest overseas order in its history [8] - *ST Xinyan's stock will resume trading on December 24, 2025, following a capital increase plan that will raise its total share capital to 3.29 billion shares [9] Group 4 - Ningbo Construction's subsidiary signed a construction contract worth 428 million yuan for an engineering project with a duration of 990 days [11] - Lianhuan Pharmaceutical's subsidiary received approval for a drug that passed the consistency evaluation for generic drugs, enhancing its market competitiveness [12] - Zhongjie Automotive received a project designation for a new electric air conditioning compressor, with expected sales of approximately 29.86 million USD over its lifecycle [13] Group 5 - Biopharmaceuticals' major shareholder plans to increase holdings by 50 million to 100 million yuan, indicating confidence in the company's future [14] - Haizheng Pharmaceutical's subsidiary received approval for a veterinary drug product, expanding its product offerings in the animal health sector [15] - *ST Songfa's subsidiary signed contracts for the construction of 8 vessels, with a total contract value between 200 million to 400 million USD [16] Group 6 - Shandong Pharmaceutical Glass announced the resignation of its chairman due to age reasons, indicating a potential leadership transition [17] - Xinno Wei's subsidiary received approval for a clinical trial of a monoclonal antibody drug, indicating advancements in its drug development pipeline [18] - Ningbo Huaxiang's subsidiary secured an order for robot joints, expected to positively impact future business performance [19][20] Group 7 - China Resources Double Crane's subsidiary received approval for a clinical trial of a drug aimed at treating a genetic eye disease, reflecting ongoing R&D efforts [21] - Huaxin Technology's shareholders set a transfer price of 56.69 yuan per share for a block of shares, indicating active shareholder engagement [22] - Xinhua Net announced the resignation of its president due to job relocation, suggesting potential changes in management [23] Group 8 - Taiji Group plans to transfer a 40% stake in a subsidiary to focus on its core pharmaceutical business, enhancing operational efficiency [24] - Huaxin Construction's shareholder plans to increase holdings by 200 million to 400 million yuan, reflecting confidence in the company's prospects [25] - Dongjie Intelligent is planning to issue shares and cash for asset acquisition, with stock trading suspended until further notice [26] Group 9 - Wanrun New Energy was designated as a delivery warehouse for lithium carbonate futures, indicating its strategic position in the market [27] - Prolo Pharmaceutical's subsidiary received a drug registration certificate for an influenza treatment, expanding its product range [28] - Saiwu Technology invested 5 million yuan in a private equity fund focused on smart vehicles and energy innovation, indicating strategic investment in growth sectors [29] Group 10 - Bohui Innovation's subsidiary received approval for a clinical trial of an immunoglobulin drug, indicating progress in its product development [30] - Bohui Innovation's subsidiary also received a drug registration certificate for a coagulation factor product, enhancing its therapeutic offerings [31] - Hanghua Co. plans to allocate 146 million yuan of surplus fundraising for a new green printing materials project, reflecting a commitment to sustainability [32] Group 11 - Nova Star Cloud obtained a loan commitment letter from a bank for a share repurchase plan, indicating financial support for its capital management strategy [33] - Jimin Health established a joint venture for technology innovation, indicating a strategic move to enhance its technological capabilities [34] - Huili Pharmaceutical received a drug registration certificate for a medication used in treating digestive ulcers, expanding its product portfolio [35]

Core Viewpoint - Jimin Health (603222.SH) has announced the establishment of a joint venture with Hubei Military-Civilian Technology Innovation Co., Ltd., with a registered capital of 600 million RMB [1] Group 1: Joint Venture Details - The joint venture will have a registered capital of 600 million RMB, with Jimin Health contributing 294 million RMB for a 49% stake [1] - Hubei Military-Civilian Technology Innovation Co., Ltd. will contribute 306 million RMB for a 51% stake [1] - Both parties will contribute cash for their respective stakes in the joint venture [1] Group 2: Implementation and Registration - The board of directors of Jimin Health approved the proposal to establish the joint venture during its sixth session's second meeting [1] - The company has completed the establishment of the joint venture and has obtained the registration certificate [1] - The management team has been authorized to handle the implementation of the relevant plans and procedures [1]

证券代码：603222 证券简称：济民健康 公告编号：2025-063 济民健康管理股份有限公司 关于合资公司设立完成的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、发起设立合资公司的基本情况 二、设立合资公司的进展情况 近日，公司已完成合资公司的设立工作，并取得了注册登记证明文件，相关 信息如下： 1、名称：湖北济民军民科技创新有限公司 2、统一社会信用代码：91420117MAK497JB60 3、类型：其他有限责任公司 4、注册资本：陆亿元 5、法定代表人：贺怡帆 6、成立日期：2025 年 12 月 18 日 7、注册地址: 湖北省武汉市新洲区辛冲街东城社区里闹南路 32 号 8、经营范围：一般项目:技术服务、技术开发、技术咨询、技术交流、技术 转让、技术推广；集成电路设计；软件开发；信息系统集成服务；信息技术咨询 服务。(除许可业务外,可自主依法经营法律法规非禁止或限制的项目) 特此公告。 济民健康管理股份有限公司董事会 2025 年 12 月 24 日 2025 年 12 月 12 日，济民健康管理股份 ...

Group 1 - A new company named Hubei Jimin Military-Civilian Technology Innovation Co., Ltd. has been established with a registered capital of 600 million RMB [1] - The legal representative of the company is He Yifan, and it is wholly owned by Jimin Health (603222) [1] - The business scope of the new company includes integrated circuit design, software development, information system integration services, and information technology consulting services [1]

证券代码：603222 证券简称：济民健康 公告编号：2025-062 济民健康管理股份有限公司 关于完成工商变更登记并换发营业执照的公告 住所：浙江省台州市黄岩区北院路 888 号 统一社会信用代码：91330000610008739T 经营范围：一般项目:健康咨询服务(不含诊疗服务)；技术服务、技术开发、 名称：济民健康管理股份有限公司 注册资本：伍亿贰仟伍佰零玖万零陆佰壹拾伍元 类型：其他股份有限公司（上市） 成立日期：1996 年 12 月 24 日 法定代表人：田云飞 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 济民健康管理股份有限公司（以下简称"公司"）分别于 2025 年 11 月 13 日和 2025 年 12 月 1 日召开的第五届董事会第二十三次会议和 2025 年第一次临 时股东会，审议通过了《关于取消监事会并修订<公司章程>的议案》；于 2025 年 12 月 2 日召开第六届董事会第一次会议，审议通过《关于聘任公司总裁的议 案》，同意聘任田云飞先生为公司总裁，任职自董事会审议通过之日至第六届董 事 ...

Group 1 - Shouyao Holdings is planning to issue H-shares and list on the Hong Kong Stock Exchange, with discussions ongoing with intermediaries regarding the specifics of the listing [1] - Jiangsu Guoxin's subsidiary, Guoxin Mazhou, has completed the trial operation of a 1000MW coal-fired power unit, which is set to officially commence operations on December 12, 2025 [2] - Yuekang Pharmaceutical's mRNA tumor vaccine has received clinical trial approval from the National Medical Products Administration for treating advanced solid tumors [3] Group 2 - Dongli New Science plans to invest 666 million yuan in the restructuring of SAIC Hongyan, acquiring approximately 14.66% equity post-restructuring [4] - Longsheng Technology is set to invest approximately 350 million yuan in the establishment of an intelligent robot innovation center in Wuxi [5] - Shangwei Co. has received a government subsidy of 2.212 million yuan, which accounts for 13.53% of its audited net profit for 2024 [6] Group 3 - Anglikang has received drug registration certificates for Diclofenac Sodium Enteric-Coated Tablets and approval for a supplemental application for Sacubitril/Valsartan Sodium Tablets [7] - Guangzhou Development has received acceptance notices for the registration of 8 billion yuan in medium-term notes and 6 billion yuan in short-term financing bonds [8] - Kebo Da plans to increase capital by 21.2 million euros (approximately 174 million yuan) in its wholly-owned subsidiary in Germany [9][10] Group 4 - Changguang Huaxin has received a total of 11.6672 million yuan in government subsidies, including 8.0552 million yuan related to income [11] - Haizheng Pharmaceutical's subsidiary has received a European Pharmacopoeia suitability certificate for its raw material [12] - Qianjin Pharmaceutical's subsidiary has received a drug registration certificate for Lurasidone Hydrochloride Tablets, used for treating schizophrenia [13] Group 5 - Daimai Co. has received a warning letter from the Shanghai Securities Regulatory Bureau due to failure to timely disclose a significant event related to a fire incident [14] - ST Changyao's subsidiary has recently ceased production due to financial difficulties and competitive pressures in the photovoltaic industry [15] - Guodian Power is investing in the construction of a 2×1000MW expansion project at the Ganbi Power Plant, with a total dynamic investment of 7.218 billion yuan [16] Group 6 - Kaichuang International's subsidiary has completed the handover of a tuna purse seine vessel, expected to be operational by 2026 [16] - Tieke Rail plans to sign an energy management agreement for a distributed photovoltaic project, which is expected to save approximately 1.441 million yuan in electricity costs over 25 years [18] - Bailian Co. plans to sign a land compensation agreement with Friendship Logistics, with a total compensation of 103 million yuan [19] Group 7 - Dayu Water-saving's subsidiary has been pre-awarded two high-standard farmland construction projects, with total expected amounts of 137 million yuan and 135 million yuan respectively [20] - Tianma Technology reported a total eel output of approximately 1197.15 tons in November, with sales prices ranging from 53,000 yuan/ton to 89,000 yuan/ton [21] - Guorui Technology's subsidiary has been shortlisted for the GXLF project with a bid of 76 million yuan [22] Group 8 - Qingdao Food's deputy general manager has resigned for personal reasons [23] - Guosheng Zhike plans to use up to 900 million yuan of idle funds for cash management [24] - Guodian Nanrui plans to use up to 23 billion yuan of idle funds for entrusted wealth management [25] Group 9 - Jiahuan Energy plans to merge its wholly-owned subsidiary, Zhejiang Jiahuan Hydrogen Peroxide Co., Ltd., through an overall absorption merger [26] - Ganyue Expressway reported vehicle toll service revenue of 309 million yuan for November [27] - Jinling Hotel's chairman has resigned due to work changes [28] Group 10 - Lisheng Pharmaceutical's subsidiary has received drug registration certificates for Apremilast Tablets [29] - Baotai has received a positive opinion from the European Medicines Agency for Gotenfia® for various inflammatory conditions [30] - ST Zhisheng has been awarded a smart city governance project with a bid amount of 104 million yuan [31] Group 11 - Chenxi Aviation and its related personnel have received administrative regulatory measures from the Shaanxi Securities Regulatory Bureau due to financial reporting issues [32] - Portong Medical has appointed Xia Canglan as the new deputy general manager [33] - Maide Medical plans to repurchase shares with a total amount between 20 million and 40 million yuan [34] Group 12 - Jimin Health plans to establish a joint venture with a total investment of 600 million yuan, focusing on AI and software development [35] - Beilu Pharmaceutical has received a drug registration certificate for Pioglitazone Metformin Tablets [36] - Hainan Mining plans to entrust the overall management of the Shiluo Iron Mine to a construction company for three years, with a total contract amount of approximately 818 million yuan [38] Group 13 - Huiyu Pharmaceutical has received a drug registration certificate for Nicardipine Hydrochloride Injection [39] - Baoland has received a government subsidy of 10 million yuan related to income [40] - Qingdao Port has terminated the acquisition of 100% equity in an oil company and 50% equity in Rizhao Shihua due to regulatory concerns [41]

Core Viewpoint - The company plans to establish a joint venture with Hubei Military-Civilian Technology Innovation Co., Ltd., aiming to enhance its core competitiveness and sustainable development through strategic asset integration and industry transformation [1] Investment Details - The registered capital of the joint venture, Hubei Jimin Military-Civilian Technology Innovation Co., Ltd., is set at 600 million yuan, with the company contributing 294 million yuan for a 49% stake, while the military-civilian technology firm will invest 306 million yuan for a 51% stake [1] Business Context - The company's main business includes medical services, medical devices, and large-volume infusion products, which have faced pressure due to intensified industry competition and external factors such as U.S. tariff policies, leading to a decline in overall performance [1] Strategic Purpose - The establishment of the joint venture is part of the company's long-term strategic planning, focusing on nurturing and integrating quality asset targets to promote industry transformation and upgrade [1]